1-20 of 24
Glenn Heller
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)

Jeffrey L. Jensen, Olivia Bobek, Irenaeus C. C. Chan, Brian C. Miller, David W. Hillman, Glenn Heller, Todd Druley, Andrew J. Armstrong, Michael J. Morris, Matthew I. Milowsky, Himisha Beltran, Kelly L. Bolton, Catherine C. Coombs
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF10.
https://doi.org/10.1158/1078-0432.CCR-24-0803
Published: 18 September 2024
View article titled, Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Open the PDF for Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer

Noura J. Choudhury, W. Victoria Lai, Alex Makhnin, Glenn Heller, Juliana Eng, Bob Li, Isabel Preeshagul, Fernando C. Santini, Michael Offin, Kenneth Ng, Paul Paik, Christina Larsen, Michelle S. Ginsberg, Yvonne Lau, Xinyuan Zhang, Marina K. Baine, Natasha Rekhtman, Charles M. Rudin
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3697–3703.
https://doi.org/10.1158/1078-0432.CCR-23-3383
Published: 03 September 2024
View article titled, A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer
Open the PDF for A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2920–2927.
https://doi.org/10.1158/1078-0432.CCR-20-4650
Published: 15 May 2021
View article titled, Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <em>EGFR</em> Exon 20 Insertions
Open the PDF for Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <em>EGFR</em> Exon 20 Insertions in another window
Includes: Supplementary data
Journal Articles

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knezevic, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8): 2209–2215.
https://doi.org/10.1158/1078-0432.CCR-20-4023
Published: 15 April 2021
View article titled, Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer
Open the PDF for Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer in another window
Journal Articles

The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer

Adam J. Schoenfeld, Chai Bandlamudi, Jessica A. Lavery, Joseph Montecalvo, Azadeh Namakydoust, Hira Rizvi, Jacklynn Egger, Carla P. Concepcion, Sonal Paul, Maria E. Arcila, Yahya Daneshbod, Jason Chang, Jennifer L. Sauter, Amanda Beras, Marc Ladanyi, Tyler Jacks, Charles M. Rudin, Barry S. Taylor, Mark T.A. Donoghue, Glenn Heller, Matthew D. Hellmann, Natasha Rekhtman, Gregory J. Riely
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5701–5708.
https://doi.org/10.1158/1078-0432.CCR-20-1825
Published: 02 November 2020
View article titled, The Genomic Landscape of <em>SMARCA4</em> Alterations and Associations with Outcomes in Patients with Lung Cancer
Open the PDF for The Genomic Landscape of <em>SMARCA4</em> Alterations and Associations with Outcomes in Patients with Lung Cancer in another window
Includes: Supplementary data
Journal Articles

The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population

Glenn Heller, Karim Fizazi, Robert McCormack, Arturo Molina, David MacLean, Iain J. Webb, Fred Saad, Johann S. de Bono, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (8): 1967–1973.
https://doi.org/10.1158/1078-0432.CCR-16-1224
Published: 13 April 2017
View article titled, The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population
Open the PDF for The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population in another window
Includes: Supplementary data
Journal Articles

Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib

Emily C. Zabor, Glenn Heller, Lawrence H. Schwartz, Paul B. Chapman
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1341–1347.
https://doi.org/10.1158/1078-0432.CCR-15-1441
Published: 14 March 2016
View article titled, Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Open the PDF for Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAF<sup>V600E</sup>-Mutated Metastatic Melanoma Patients Treated with Vemurafenib in another window
Includes: Supplementary data
Journal Articles

A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Neeta Pandit-Taskar, Joseph A. O'Donoghue, Jeremy C. Durack, Serge K. Lyashchenko, Sarah M. Cheal, Volkan Beylergil, Robert A. Lefkowitz, Jorge A. Carrasquillo, Danny F. Martinez, Alex Mak Fung, Stephen B. Solomon, Mithat Gönen, Glenn Heller, Massimo Loda, David M. Nanus, Scott T. Tagawa, Jarett L. Feldman, Joseph R. Osborne, Jason S. Lewis, Victor E. Reuter, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5277–5285.
https://doi.org/10.1158/1078-0432.CCR-15-0552
Published: 30 November 2015
View article titled, A Phase I/II Study for Analytic Validation of <sup>89</sup>Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
Open the PDF for A Phase I/II Study for Analytic Validation of <sup>89</sup>Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Analysis of circulating prostate tumor cells by fluorescence in situ hybridization

Margaret Leversha, Long Cao, Zahra Asgari, Daniel Danila, Rita Gonzalez-Espinosa, Aseem Anand, Hans Lilja, Glenn Heller, Martin Fleisher, Howard Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): PL07.
Published: 15 August 2014
View article titled, Analysis of circulating prostate tumor cells by fluorescence in situ hybridization
Journal Articles

Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo

Emanuela Romano, Marco Rossi, Gudrun Ratzinger, Maria-Angeles de Cos, David J. Chung, Katherine S. Panageas, Jedd D. Wolchock, Alan N. Houghton, Paul B. Chapman, Glenn Heller, Jianda Yuan, James W. Young
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1984–1997.
https://doi.org/10.1158/1078-0432.CCR-10-3421
Published: 31 March 2011
View article titled, Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em>
Open the PDF for Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation <em>In Vitro</em>, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

Margaret A. Leversha, Jialian Han, Zahra Asgari, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Aseem Anand, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2091–2097.
https://doi.org/10.1158/1078-0432.CCR-08-2036
Published: 16 March 2009
View article titled, Fluorescence <em>In situ</em> Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer
Open the PDF for Fluorescence <em>In situ</em> Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer in another window
Journal Articles

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

Daniel C. Danila, Glenn Heller, Gretchen A. Gignac, Rita Gonzalez-Espinoza, Aseem Anand, Erika Tanaka, Hans Lilja, Lawrence Schwartz, Steven Larson, Martin Fleisher, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7053–7058.
https://doi.org/10.1158/1078-0432.CCR-07-1506
Published: 03 December 2007
View article titled, Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Open the PDF for Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer in another window
Journal Articles

Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

David R. Shaffer, Margaret A. Leversha, Daniel C. Danila, Oscar Lin, Rita Gonzalez-Espinoza, Bin Gu, Aseem Anand, Katherine Smith, Peter Maslak, Gerald V. Doyle, Leon W.M.M. Terstappen, Hans Lilja, Glenn Heller, Martin Fleisher, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2023–2029.
https://doi.org/10.1158/1078-0432.CCR-06-2701
Published: 02 April 2007
View article titled, Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
Open the PDF for Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer in another window
Journal Articles

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

David B. Solit, S. Percy Ivy, Catherine Kopil, Rachel Sikorski, Michael J. Morris, Susan F. Slovin, W. Kevin Kelly, Anthony DeLaCruz, Tracy Curley, Glenn Heller, Steven Larson, Lawrence Schwartz, Merrill J. Egorin, Neal Rosen, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1775–1782.
https://doi.org/10.1158/1078-0432.CCR-06-1863
Published: 15 March 2007
View article titled, Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
Open the PDF for Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study

Rochelle Bagatell, Lia Gore, Merrill J. Egorin, Richard Ho, Glenn Heller, Nichole Boucher, Eleanor G. Zuhowski, James A. Whitlock, Stephen P. Hunger, Aru Narendran, Howard M. Katzenstein, Robert J. Arceci, Jessica Boklan, Cynthia E. Herzog, Luke Whitesell, S. Percy Ivy, Tanya M. Trippett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1783–1788.
https://doi.org/10.1158/1078-0432.CCR-06-1892
Published: 15 March 2007
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of 17-<em>N</em>-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study in another window
Journal Articles

The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer

Howard I. Scher, Mary Warren, Glenn Heller
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1488–1492.
https://doi.org/10.1158/1078-0432.CCR-06-1885
Published: 01 March 2007
View article titled, The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer
Open the PDF for The Association Between Measures of Progression and Survival in Castrate-Metastatic Prostate Cancer in another window
Journal Articles

Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer

David Feltquate, Luke Nordquist, Caitlin Eicher, Michael Morris, Oren Smaletz, Susan Slovin, Tracy Curley, Andrew Wilton, Martin Fleisher, Glenn Heller, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7414–7421.
https://doi.org/10.1158/1078-0432.CCR-06-1496
Published: 22 December 2006
View article titled, Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer
Open the PDF for Rapid Androgen Cycling as Treatment for Patients with Prostate Cancer in another window
Journal Articles

Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy

Susan F. Slovin, Andrew S. Wilton, Glenn Heller, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8669–8673.
https://doi.org/10.1158/1078-0432.CCR-05-1668
Published: 16 December 2005
View article titled, Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy
Open the PDF for Time to Detectable Metastatic Disease in Patients with Rising Prostate-Specific Antigen Values following Surgery or Radiation Therapy in another window
Journal Articles

Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards

Howard I. Scher, Michael J. Morris, William K. Kelly, Lawrence H. Schwartz, Glenn Heller
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (14): 5223–5232.
https://doi.org/10.1158/1078-0432.CCR-05-0109
Published: 20 July 2005
View article titled, Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
Open the PDF for Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards in another window
Journal Articles

Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy

Michael J. Morris, Timothy Akhurst, Steven M. Larson, Marisa Ditullio, Elaina Chu, Karen Siedlecki, David Verbel, Glenn Heller, W. Kevin Kelly, Susan Slovin, Lawrence Schwartz, Howard I. Scher
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (9): 3210–3216.
https://doi.org/10.1158/1078-0432.CCR-04-2034
Published: 02 May 2005
View article titled, Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy
Open the PDF for Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy in another window